In vitro demonstration of cryosurgical augmentation of tumor immunity.
C57B1 mice bearing methylcholanthrene-induced fibrosarcomas (MCA-10) and receiving a single cryosurgical treatment to those tumors showed significantly greater humoral and lymphocyte-mediated cytotoxicity to MCA-10 target cells than did untreated tumor-bearing animals or mice which had undergone tumor amputation. Sera and lymphocytes from normal animals receiving crycosurgery demonstrated no immunity to the MCA-10 target cells. Specific immunity to the MCA-10 line following tumor cryosurgery was demonstrated since lymphocytes and sera from cryosurgically treated tumor-bearing mice were not cytotoxic to a different methylcholanthrene-induced sarcoma (MCAP) in C57 mice or a malignant melanoma (S91) being transferred in Balb/C mice. It can be concluded that cryosurgical treatment of the MCA-10 sarcoma does not produce heightened immunity to H-2 transplantation antigens, nor does it nonspecifically stimulate the immune system. Instead, the result of tumor cryosurgery appears to be a boosting of the immune response to the tumor-specific antigens of the sarcoma.
D000818:Animals; D000917:Antibody Formation; D000951:Antigens, Neoplasm; D003165:Complement System Proteins; D003452:Cryosurgery; D003601:Cytotoxicity Tests, Immunologic; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology* / Q000601:surgery; D006680:HLA Antigens; D007111:Immunity, Cellular; D008214:Lymphocytes / Q000276:immunology; D008545:Melanoma / Q000276:immunology*; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D012513:Sarcoma, Experimental / Q000139:chemically induced
D000951:Antigens, Neoplasm; D006680:HLA Antigens; D008748:Methylcholanthrene; D003165:Complement System Proteins